Anticancer therapy targeting the apoptotic pathway

Lancet Oncology

Volumn 4, Issue 12, 2003, Pages 721-729

  Hu, Wei ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AAG 17; ADAPTOR PROTEIN; ADVEXIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CANFOSFAMIDE; CASPASE; DOCETAXEL; FAS LIGAND; GEFITINIB; GLUTATHIONE DERIVATIVE; HEAT SHOCK PROTEIN 70; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; NEW DRUG; OBLIMERSEN; ONYX 015; PLATINUM DERIVATIVE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN P53; SURVIVIN; TAXANE DERIVATIVE; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; CANCER THERAPY; CELL COUNT; CELL KILLING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; TARGET CELL; THROMBOSIS; TUMOR CELL;

EID: 0346873049     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01277-4     Document Type: Review

References (98)

1. Jaattela M. Programmed cell death: many ways for cells to die decently. Ann Med 2002; 34: 480-88.
2. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1: 111-21.
3. Korsmeyer SJ, Wei MC, Saito M, et al. Proapoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73.
4. Sun XM, MacFarlane M, Zhuang J, et al. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-60.
5. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10: 169-77.
6. Kim R, Tanabe K, Uchida Y, et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis: the contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 2002; 50: 343-52.
7. Park SJ, Kim YY, Ju JW, et al. Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation. Biochem Biophys Res Commun 2001; 289: 1205-10.
8. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
9. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 2003; 10: 36-44.
10. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
11. Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20: 4258-69.
12. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 2002; 13: 199-207.
13. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-26.
14. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
15. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-76.
16. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-36.
17. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
18. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-86.
19. Reed JC, Miyashita T, Takayama S, et al. BCL2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23-32.
20. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-80.
21. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-99.
22. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-911.
23. Henry H, Thomas A, Shen Y, White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002; 21: 748-60.
24. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199: 275-88.
25. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003; 169: 1219-28.
26. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002; 111: 147-50.
27. Deveraux QL, Leo E, Stennicke HR, et al. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. Embo J 1999; 18: 5242-51.
28. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. Embo J 1998; 17: 2215-23.
29. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. Embo J 1997; 16: 6914-25.
30. Cheng JQ, Jiang X, Fraser M, et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 2002; 5: 131-46.
31. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-61.
32. Verhagen AM, Silke J, Ekert PG, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem 2002; 277: 445-54.
33. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-84.
34. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
35. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001; 34: 207-12.
36. Sela B. Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence. Harefuah 2002; 141: 103-07, 123.
37. Chen J, Jin S, Tahir SK, et al. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J Biol Chem 2003; 278: 486-90.
38. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001; 159: 387-97.
39. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795-804.
40. Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000; 21: 1218-26.
41. Creagh EM, Sheehan D, Cotter TG. Heat shock proteins-modulators of apoptosis in tumour cells. Leukemia 2000; 14: 1161-73.
42. Mosser DD, Caron AW, Bourget L, et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000; 20: 7146-59.
43. Saleh A, Srinivasula SM, Balkir L, et al. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2000; 2: 476-83.
44. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469-75.
45. Hainaut P, Milner J. Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. Embo J 1992; 11: 3513-20.
46. Koskinen PJ, Sistonen L, Evan G, Morimoto R, Alitalo K. Nuclear colocalization of cellular and viral myc proteins with HSP70 in myc-overexpressing cells. J Virol 1991; 65: 842-51.
47. Takayama S, Bimston DN, Matsuzawa S, et al. BAG1 modulates the chaperone activity of Hsp70/Hsc70. Embo J 1997; 16: 4887-96.
48. Ravagnan L, Gurbuxani S, Susin SA, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001; 3: 839-43.
49. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-79.
50. Hu W, Wu WG, Chen L, et al. Proteomic identification of Heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 2003; in press.
51. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000; 20: 4087-96.
52. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
53. Kornblau SM, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opin Investig Drugs 1999; 8: 2027-57.
54. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-46.
55. De Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001; 20: 51-56.
56. Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61: 1645-51.
57. Xiang H, Fox JA, Totpal K, et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 2002; 21: 3611-19.
58. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-67.
59. Ciardiello F, Tortora G. Inhibition of bcl-2 as cancer therapy. Ann Oncol 2002; 13: 501-02.
60. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleoticle) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28 (4 suppl 15): 67-70.
61. Leung S, Miyake H, Zellweger T, et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001; 91: 846-50.
62. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-83.
63. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13: 539-45.
64. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkins lymphoma. J Clin Oncol 2000; 18: 1812-23.
65. Satyam A, Hocker MD, Kane-Maguire KA, et al. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J Med Chem 1996; 39: 1736-47.
66. Rosario LA, O'Brien ML, Henderson CJ, et al. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol 2000; 58: 167-74.
67. Izbicka E, Lawrence R, Cerna C, et al. Activity of TER286 against human tumor colony-forming units. Anticancer Drugs 1997; 8: 345-48.
68. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
69. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13: 863-75.
70. Kavanagh J, Kudelka, AP, Spriggs DR, et al. Phase 2 study of TLK 286 (GST p1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer. ASCO 2002; 831 (abstr).
71. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
72. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
73. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
74. Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol 2002; 29 (6 Suppl 17): 26-33.
75. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8 (4 Suppl): S49-54.
76. L'Allemain G. Update on the proteasome inhibitor PS341. Bull Cancer 2002; 89: 29-30.
77. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001; 28: 613-19.
78. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001; 116: 637-46.
79. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001; 8: 1487-503.
80. Wright J, Hillsamer VL, Gore-Langton RE, Cheson BD. Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341. Oncology 2000; 14: 1589-90, 1593-94, 1597.
81. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18: 109-21.
82. Henderson C, Mizzau M, Paroni G, et al. Role of caspases, bid and p53 in the apoptotic response triggered by histone deacetylase inhibitors TSA and SAHA. J Biol Chem 2003; 278: 12579-89.
83. Medina V, Edmonds B, Young GP, et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57: 3697-707.
84. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-07.
85. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9: 322-32.
86. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
87. Piekarz R. Histone deacetylase inhibitor for the treatment of pheripheral or cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 2001; 20: 323B.
88. Cohen EE, Rodin CM. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 1770-75.
89. Clayman GL, Dreiling L. Local delivery for gene therapy. Curr Oncol Rep 1999; 1: 138-43.
90. Brukner I. INGN-201. Introgen Therapeutics. Curr Opin Investig Drugs 2001; 2: 1776-85.
91. Clayman GL, EI-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-32.
92. Kelland LR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Investig Drugs 2003; 12: 413-21.
93. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305-15.
94. Hostein I, Robertson D, DiStefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003-09.
95. Neckers L. Development of small molecule hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 2003; 10: 733-39.
96. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999; 17: 361-73.
97. Agnew EB, Wilson RH, Grem JL, et al. Measurement of the novel antitumor agent 17-(allylamino) A 7-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 755: 237-43.
98. Los M, Burek CJ, Stroh C, et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003; 8: 67-77.